Hello FPC folks,
Mustang Bio announces some initial and fairly substantial data involving their Car-T PSCA positive drug candidate MB-105. Impressive initial results from a patient this was administered to in the trial... In a 73-year-old male patient with PSCA-positive mCRPC who was treated with MB-105 and lymphodepletion (a standard CAR T pre-conditioning regimen) after failing eight prior therapies, MB-105 demonstrated on day 28 a 94 percent reduction in prostate-specific antigen (PSA), near complete reduction of measurable soft tissue metastasis by computerized tomography, and improvement in bone metastases by magnetic resonance imaging The trial is enrolling 33 candidates for Car-T treatment with MB-105 for MCRPC.
globenewswire.com/news-rele...
The clinical trial is STILL RECRUITING--out of City of Hope....some info:
clinicaltrials.gov/ct2/show...
Next, we learn that exercise helps to fight cancer through changing the metabolism of cytotoxic T cells-see below:
sciencedaily.com/releases/2...
Lastly, The FDA approval of Ezra AI for MRI making diagnosis faster and cheaper...
prnewswire.com/news-release...
The Science is Coming !!! and it gives us....HOPE !!!
Don Pescado